Literature DB >> 26387707

Participants' Views of Retention Materials Used in the PLCO Cancer Screening Trial.

Shannon M Pretzel1, Tara S Andrews2, Karen Broski2, Jeffery C Childs3, Lisa H Gren4, Sheryl L Ogden5, Jerome Mabie6, Brett Thomas6, Heather M Rozjabek7, Pamela M Marcus8.   

Abstract

OBJECTIVE: To obtain information from participants in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial regarding their perception of the retention materials employed by the screening centers. Also, to determine the viability of using email or the internet as a data collection tool with an older population.
DESIGN: Three of ten PLCO screening centers queried participants towards the end of the study (2010) as to their opinions of the various retention materials and whether they would have been willing to use electronic communication for study activities, had the option been available.
SETTING: The questionnaires were administered by mail, and responses were returned to the originating screening center. PARTICIPANTS: The participants in this study consisted of all the active participants at three PLCO screening centers: the University of Colorado Anschutz Medical Campus, the University of Utah, and Henry Ford Health System.
METHODS: A short, self-administered questionnaire was mailed to all active participants at three PLCO centers (n=41,482). This was a one-time mailing with no follow-up, as the responses were designed to be anonymous in order to obtain the most honest responses.
RESULTS: The response rate was 62%. Of respondents, 97% reported their PLCO experience was good or excellent. Nearly 50% of respondents indicated that receipt of an annual newsletter made them more likely to participate; newsletter features they reported as most important were those that conveyed information on cancer, study findings, and how their data were being used. Results did not support study coordinators' suppositions that receipt of a token gift or birthday card by participants was important for retention. Fewer than 30% of respondents indicated that they would have been unwilling to use a secure website to complete study forms.
CONCLUSION: These data indicate the importance of querying participants rather than relying on impressions of study staff, and also indicate that the internet will be a viable means of data collection in future prevention studies that include older Americans.
© 2015 Marshfield Clinic.

Entities:  

Keywords:  Cancer; Internet usage; Mass screening; Patient compliance; Randomized controlled trial as subject; USA

Mesh:

Year:  2015        PMID: 26387707      PMCID: PMC4720510          DOI: 10.3121/cmr.2015.1274

Source DB:  PubMed          Journal:  Clin Med Res        ISSN: 1539-4182


  6 in total

1.  Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial.

Authors:  Martin M Oken; Willam G Hocking; Paul A Kvale; Gerald L Andriole; Saundra S Buys; Timothy R Church; E David Crawford; Mona N Fouad; Claudine Isaacs; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Lawrence R Ragard; Joshua M Rathmell; Thomas L Riley; Patrick Wright; Neil Caparaso; Ping Hu; Grant Izmirlian; Paul F Pinsky; Philip C Prorok; Barnett S Kramer; Anthony B Miller; John K Gohagan; Christine D Berg
Journal:  JAMA       Date:  2011-10-26       Impact factor: 56.272

2.  Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy.

Authors:  Robert E Schoen; Paul F Pinsky; Joel L Weissfeld; Lance A Yokochi; Timothy Church; Adeyinka O Laiyemo; Robert Bresalier; Gerald L Andriole; Saundra S Buys; E David Crawford; Mona N Fouad; Claudine Isaacs; Christine C Johnson; Douglas J Reding; Barbara O'Brien; Danielle M Carrick; Patrick Wright; Thomas L Riley; Mark P Purdue; Grant Izmirlian; Barnett S Kramer; Anthony B Miller; John K Gohagan; Philip C Prorok; Christine D Berg
Journal:  N Engl J Med       Date:  2012-05-21       Impact factor: 91.245

3.  Promoting adherence and retention to clinical trials in special populations: a women's health initiative workshop.

Authors:  S Wilcox; S A Shumaker; D J Bowen; M J Naughton; M C Rosal; S E Ludlam; E Dugan; J R Hunt; S Stevens
Journal:  Control Clin Trials       Date:  2001-06

4.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Claudine Isaacs; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Lawrence R Ragard; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Ann W Hsing; Grant Izmirlian; Paul F Pinsky; Barnett S Kramer; Anthony B Miller; John K Gohagan; Philip C Prorok
Journal:  J Natl Cancer Inst       Date:  2012-01-06       Impact factor: 13.506

Review 5.  Systematic review identifies number of strategies important for retaining study participants.

Authors:  Karen A Robinson; Cheryl R Dennison; Dawn M Wayman; Peter J Pronovost; Dale M Needham
Journal:  J Clin Epidemiol       Date:  2007-05-10       Impact factor: 6.437

6.  Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.

Authors:  Saundra S Buys; Edward Partridge; Amanda Black; Christine C Johnson; Lois Lamerato; Claudine Isaacs; Douglas J Reding; Robert T Greenlee; Lance A Yokochi; Bruce Kessel; E David Crawford; Timothy R Church; Gerald L Andriole; Joel L Weissfeld; Mona N Fouad; David Chia; Barbara O'Brien; Lawrence R Ragard; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Patricia Hartge; Paul F Pinsky; Claire S Zhu; Grant Izmirlian; Barnett S Kramer; Anthony B Miller; Jian-Lun Xu; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  JAMA       Date:  2011-06-08       Impact factor: 157.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.